3B Blackbio DX Ltd

3B Blackbio DX recorded a robust intraday performance on 25 Nov 2025, touching a day’s high of ₹1280, marking an 8.26% rise. This surge stands out amid a broader market environment where the Sensex showed a mild decline, underscoring the stock’s notable trading momentum within the healthcare services sector.

3B Blackbio DX experienced a notable decline today, touching an intraday low of ₹1,185.3, marking a fresh 52-week low as the stock faced significant price pressure amid broader market fluctuations and sector underperformance.

Shares of 3B Blackbio DX, a player in the Healthcare Services sector, touched a fresh 52-week low of Rs.1226.1 today, marking a significant decline amid a sustained downward trend over recent sessions.

3B Blackbio DX, a small-cap healthcare services company, has experienced significant stock fluctuations, with a recent trading range indicating volatility. Technical indicators present mixed signals, reflecting complex market sentiment. Despite recent challenges compared to the Sensex, the company has demonstrated substantial long-term growth over three and five years.

3B Blackbio DX has hit a new 52-week low, reflecting a significant downturn for the small-cap healthcare services firm. The stock has underperformed its sector and experienced high volatility. Over the past year, it has declined notably, contrasting with broader market gains, while facing challenges in sales and profit metrics.

3B Blackbio DX, a small-cap healthcare services company, has faced notable volatility, reaching a 52-week low while underperforming its sector. The stock fluctuated significantly during the trading session and is currently below key moving averages, reflecting a bearish trend amid a generally positive broader market.

3B Blackbio DX, a small-cap healthcare services firm, has recently revised its evaluation amid market fluctuations. The stock has shown volatility, with notable price movements over the past week. While long-term returns have been strong, recent performance has been negative compared to broader market indices, indicating mixed results.

3B Blackbio DX has reported a flat financial performance for the quarter ending September 2025, with a decline in its score over the past three months. Despite challenges in profitability, the company achieved strong operating cash flow and record net sales, showcasing its operational strengths and revenue generation capabilities.

3B Blackbio DX Ltd., the Bhopal-based healthcare services company, reported a consolidated net profit of ₹14.71 crores in Q2 FY26, marking a modest 0.41% year-on-year growth but a healthier 16.84% sequential expansion. Despite the profit uptick, the stock remains under severe pressure, trading 41.91% below its 52-week high at ₹1,365.00, with a market capitalisation of ₹1,176 crores. The company's valuation continues to flash red signals, rated "Very Expensive" with an overall Mojo Score of just 36 out of 100—firmly in SELL territory.

3B Blackbio DX, a small-cap healthcare services company, has experienced significant stock volatility, with a current price of 1,361.20. Despite recent bearish market indicators, the company has demonstrated impressive long-term growth, achieving a 314.31% return over three years and an extraordinary 15,280.79% over ten years.

3B Blackbio DX has reached a new 52-week low of Rs. 1290.5, reflecting a significant downturn for the small-cap healthcare services company. The stock has declined over four consecutive days and has underperformed the broader market, raising concerns about its long-term growth metrics amid ongoing economic challenges.